Understand the source comparison
AOD-9604 vs Other Lipolytic Peptides: Research Comparison
This table compares AOD-9604 to other peptides used in lipolytic research protocols to clarify mechanism differences and protocol compatibility. AOD-9604 Beta-3 adrenergic receptor agonist (hGH fragment 176-191) ~2.5 hours 300mcg twice daily −20°C (lyophilised
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares AOD-9604 to other peptides used in lipolytic research protocols to clarify mechanism differences and protocol compatibility.
- AOD-9604
- Beta-3 adrenergic receptor agonist (hGH fragment 176-191)
- ~2.5 hours
- 300mcg twice daily
- −20°C (lyophilised), 2–8°C (reconstituted, 28 days max)
- Best for pure lipolytic research without growth hormone receptor activity. Highly sensitive to temperature and pH
- CJC-1295
- GHRH analogue (growth hormone release)
- 6–8 days
- 2mg weekly
- −20°C (lyophilised), 2–8°C (reconstituted, 60 days max)
- Indirect lipolysis via GH elevation. More stable than AOD-9604 but broader endocrine effects complicate isolated fat loss research
- Ipamorelin
- Ghrelin receptor agonist (growth hormone secretagogue)
- ~2 hours
- 200–300mcg 2–3x daily
- −20°C (lyophilised), 2–8°C (reconstituted, 30 days max)
- Similar dosing frequency to AOD-9604 but works via GH pulse rather than direct beta-receptor binding
- Tesamorelin
- Synthetic GHRH analogue
- ~45 minutes
- 2mg daily
- 2–8°C (pre-mixed formulation stable 30 days)
- FDA-approved for lipodystrophy research. Shortest half-life requires daily dosing, most expensive per protocol cycle
- Fragment 176-191 (generic)
- Identical to AOD-9604
- 250–500mcg twice daily
- Chemically identical to AOD-9604 but lacks acetylation modification. Slightly lower receptor affinity in some assays